EXEL News and Press, Exelixis Inc. From 02/13/23

The U.S. Food and Drug Administration (FDA) cleared Exelixis ( NASDAQ: EXEL ) and Sairopa (Sairopa) drug ADU-1805 to enter human trial to treat adults with advanced solid tumors. Sairopa had filed an investigational new drug (IND) application to evaluate the safety and pharm...

– ADU-1805 is a potential best-in-class monoclonal antibody targeting SIRPα to block the SIRPα-CD47 checkpoint – – Phase 1 study of ADU-1805 as a single agent and in a combination regimen in advanced solid tumors expected to begin second quarter of t...

The biotech industry is home to many large and prominent corporations, but there are also smaller and lesser-known drugmakers that are worth investors' consideration. Take Axsome Therapeutics (NASDAQ: AXSM) and Exelixis (NASDAQ: EXEL) , two mid-cap biotechs with plenty to look for...

Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q4 2022 Earnings Call Feb 07, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q4 2022 Earnings Call Transcript

Exelixis, Inc. (EXEL) Q4 2022 Results Conference Call February 07, 2023 05:00 PM ET Company Participants Susan Hubbard - EVP, Public Affairs and IR Mike Morrissey - President and CEO Chris Senner - CFO P.J. Haley - EVP, Commercial Vicki Goodman - Chief Medical ...

Exelixis press release ( NASDAQ: EXEL ): Q4 Non-GAAP EPS of -$0.03 beats by $0.02 . Revenue of $423.92M (-6.0% Y/Y) beats by $5.21M . Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million f...

- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 - - Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 - - G...

In stock investing, it's easy to focus on big names and blue-chip companies since they are frequently reported in financial media. Conversely, smaller companies, but with promising businesses, tend to be ignored. The latter have smaller market capitalizations and usually trade at more affordable ...

– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in February: Guggenheim Healt...

Credit Suisse has initiated Exelixis ( NASDAQ: EXEL ) with an outperform rating saying that its core medicine, Cabometyx (cabozantinib) is ma market leader and has growth potential with its pipeline. The firm has a $29 price target (67% upside based on Wednesday's close). Analyst ...